SNNA
Sienna Biopharmaceuticals, Inc.
SNNA
SNNA
Delisted
SNNA was delisted on the 16th of December, 2019.
23 hedge funds and large institutions have $1.08M invested in Sienna Biopharmaceuticals, Inc. in 2019 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 13 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
23
Holders Change
-25
Holders Change %
-52.08%
% of All Funds
0.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
4
Reduced
13
Closed
25
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$8.78K |
| 2 |
Goldman Sachs
New York
|
+$1.28K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$56 |
Top Sellers
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$2.25M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.62M |
| 3 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$660K |
| 4 |
Renaissance Technologies
New York
|
-$510K |
| 5 |
WCM
Wildcat Capital Management
New York
|
-$257K |
